AUTHORS
Jose C Villasboas, MD, Michal Kwiatek, MD, PhD2, Pier Luigi Zinzani, MD, PhD3, Mark John Bishton, PhD, MBChB4, Clémentine Sarkozy, MD,PhD5, Raúl Córdoba6, Victoria L. Campbell, PhD, MBBS, BSc, FRCPath, MRCP7, Abel Costa, MD8, Guilherme Fleury Fleury Perini I, MD9, Robert Kridel, MD10, Talal Hilal, MD11, Parth Rao12, Joanna Mikita-Geoffroy, PhD13, Lina Yang14, Matthew E. Stokes15, C. Chris Huang16, Serena Perna, MD17, Charalambos Andreadis, MD, MS18
AFFILIATIONS
1 Mayo Clinic, Rochester, Minnesota, United States
2 AidPort Clinical Trials Hospital, Skórzewo, Poland
3 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
4 University of Nottingham, Nottingham, United Kingdom
5 Institut Curie, Paris, France
6 Fundación Jiménez Díaz University Hospital, Madrid, Spain
7 NHS Lothian – Western General Hospital, Edinburgh, United Kingdom
8 Instituto D’Or de Pesquisa e Ensino (IDOR), São Paulo, Brazil
9 Hospital Israelita Albert Einstein, São Paulo, Brazil
10 University Health Network (Princess Margaret Cancer Centre), Toronto, Canada
11 Mayo Clinic, Rochester, Minnesota, United States
12 Bristol Myers Squibb, Princeton, New Jersey, United States
13 Bristol Myers Squibb, Boudry, Switzerland
14 Bristol Myers Squibb, Madison, New Jersey, United States
15 Bristol Myers Squibb, Madison, New Jersey, United States
16 Bristol Myers Squibb, Madison, New Jersey, United States
17 Bristol Myers Squibb, Madison, New Jersey, United States
18 University of California, San Francisco (UCSF), San Francisco, California, United States
ABSTRACT
Background
Pts with advanced-stage FL often require systemic treatment (Tx) with immunochemotherapy. Given the older age of many pts and indolent nature of FL, novel and convenient chemotherapy (chemo)–free approaches are needed.
GOLCA is a potential, first-in-class, oral CELMoD designed for the Tx of lymphoma, with preferential distribution to lymphoid organs and enhanced activity in lymphoma cell lines. GOLCA drives the closed, active conformation of cereblon to induce rapid and deep degradation of Ikaros and Aiolos, leading to direct cell killing and immunomodulatory activity.
Building on the promising activity of GOLCA+R in the phase 1/2 CC-99282-NHL-001 study, the phase 2 GOLSEEK-2 trial evaluated GOLCA+R in newly diagnosed, stage II–IV FL.
Methods
Pts with grade (Gr) 1, 2, or 3a FL or classic FL without prior systemic Tx who required Tx per investigator (INV) were randomized 1:1:1 to 0.2mg or 0.4mg GOLCA+R (12 cycles [C]) or INV’s choice of R-chemo (6 C). GOLCA was administered orally once daily (d 1–14 every 28 d). All pts with partial response or better could receive optional R maintenance. Primary granulocyte colony stimulating factor (G-CSF) prophylaxis was not given in GOLCA+R arms. Primary endpoint was complete metabolic response (CMR) rate for GOLCA+R at any time during the GOLCA+R combination period (INV assessed every ≈12 wk). Secondary endpoints included safety, duration of response, and progression-free survival (all arms). Exploratory endpoints included minimal residual disease (MRD). GOLSEEK-2 was a dose optimization study for GOLCA+R and not powered for comparison. No formal hypothesis testing was planned.
Results
At median follow-up of 16.2 mo, 93 pts received GOLCA 0.2mg+R (n=28), GOLCA 0.4mg+R (n=33), or R-chemo (n=32 [R-bendamustine, n=25; R-CHOP, n=7]). Of pts who received GOLCA 0.2mg+R, GOLCA 0.4mg+R, or R-chemo, median age was 63, 62, and 61 y; 45%, 55%, and 45% had high-risk FL International Prognostic Index (FLIPI) score.
Overall, 24 (86%), 23 (70%), and 31 (97%) pts who received GOLCA 0.2mg+R, GOLCA 0.4mg+R, or R-chemo completed Tx; of these, 19 (79%), 18 (78%), and 24 (77%) received maintenance (all pts who received GOLCA+R remain on Tx; 3 in R-chemo arm discontinued).
In response-evaluable pts (0.2mg, n=28; 0.4mg, n=32), CMR rates at any time during Tx with GOLCA 0.2mg+R or GOLCA 0.4mg+R were 79% (90% CI, 62.0–90.2) and 100% (90% CI, 91.1–100); ORRs were 89% and 100%. Most pts (84%) achieved CMR at first assessment with GOLCA 0.4mg+R. MRD data showed concordance with CMR rates. Subsequent diseasee progression occurred in 1 pt each with GOLCA 0.2mg and GOLCA 0.4mg. With R-chemo (n=31), CMR rate was 94% (90% CI, 81.1–98.8), and ORR was 100%. Subsequent disease progression occurred in 3 pts.
Median relative dose intensity of GOLCA was 99% and 94% with 0.2mg and 0.4mg. Discontinuation due to Tx-related AE occurred in 0 pts with GOLCA 0.2mg+R and 4 (12%) with GOLCA 0.4mg+R. Tx-emergent adverse events (TEAEs) were primarily hematological; nonhematological TEAEs were infrequent and mostly low Gr. Neutropenia, an expected on-target and reversible effect of GOLCA, was the most common Gr ≥3 TEAE (0.2mg, 54%; 0.4mg, 85%). Febrile neutropenia rate was low (Gr ≥3: 0.2mg, 0%; 0.4mg, 6%). Gr ≥3 infections occurred in 7% and 21%. With 0.4mg, of 28 pts with Gr ≥3 neutropenia, 5 had concurrent Gr ≥3 infection. Median time to resolution of Gr ≥3 neutropenia was 8.0 d. Neutropenia was transient and managed with G-CSF (secondary prophylaxis) and dose modification; 1 pt discontinued due to neutropenia. In GOLCA 0.4mg+R arm, 2 deaths were reported. Both pts had stage IV FL with intermediate/high-risk FLIPI and achieved CMR after 3 C. One pt died in C4 due to E.coli sepsis, and 1 pt died in C10 of unknown cause. With R-chemo, Gr ≥3 neutropenia occurred in 47%; febrile neutropenia in 0%; Gr ≥3 infections in 13%; concurrent Gr ≥3 neutropenia and Gr ≥3 infection in 2/15 (13%); and Tx-related discontinuation in 1 (3%). No deaths were reported in the R-chemo arm.
Conclusion
GOLSEEK-2 results confirm the strong antitumor efficacy of GOLCA+R, with a high CMR rate and most pts achieving CMR and MRD negativity at first assessment with GOLCA 0.4mg+R. R-chemo also performed well in this noncomparative, dose optimization study. Safety was consistent with the known profile of GOLCA+R. These results support continued evaluation of GOLCA+R as a highly active and convenient chemo-free regimen for newly diagnosed advanced-stage FL.
DISCLOSURES
Jose C Villasboas, MD: Regeneron Pharmaceuticals, Inc. - Research Funding; Bristol Myers Squibb/Celgene - Research Funding; Genentech/Roche - Research Funding; Aptose Biosciences - Research Funding; Enterome - Research Funding; Epizyme - Research Funding; Kite/Gilead - Consultancy (Includes expert testimony); Curio Science - Consultancy (Includes expert testimony); TG Therapeutics - Consultancy (Includes expert testimony); Regeneron Pharmaceuticals, Inc. - Consultancy (Includes expert testimony)